Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAmubarvimab/romlusevimabAmubarv../r.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Amubarvimab/romlusevimab for COVID-19
3 studies from 87 scientists
1,474 patients in 1 country
Statistically significant lower risk for viral clearance.
2 studies from 2 independent teams (both from the same country) show significant improvements.
Efficacy is variant dependent.
COVID-19 Amubarvimab/romlusevimab studies. Oct 2024. c19early.org
0 0.5 1 1.5+ All studies 18% With exclusions 61% Mortality 18% Hospitalization 37% Viral clearance 7% RCTs 61% RCT mortality 61% Early 91% Late -34% Favorsamubarvimab Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Efficacy is variant dependent. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Casadevall, Choudhary, Günther, Leducq. Recent:
Evering
Casadevall.
Amubarvimab/romlusevimab was adopted in 1 country. Submit updates/corrections. Summary.
Oct 7
Covid Analysis Amubarvimab/romlusevimab for COVID-19: real-time meta analysis of 3 studies
Statistically significant lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant improvements. Meta analysis using the most serious outcome reported shows 18% [-156..
Aug 16
Evering et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102787 Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
91% lower mortality (p=0.006), 20% higher PASC (p=0.39), 61% lower hospitalization (p=0.0008), and 67% lower combined mortality/hospitalization (p<0.0001). RCT 780 high-risk non-hospitalized COVID-19 patients showing significantly lower risk of hospitalization or death through 36 weeks, but no significant difference in long COVID with amubarvimab/romlusevimab treatment compared to placebo.
Aug 11
Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268 Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Aug 8
Casadevall et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408 Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship
Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod..
Apr 19
Yalan et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7 Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
71% higher mortality (p=0.35), 8% higher ICU admission (p=0.8), 8% shorter hospitalization (p=0.004), and 7% faster viral clearance (p=0.004). Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy fo..
Sep 6
2022
Hao et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.983505 Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
Phase 1 RCT with 44 healthy adults showing BRII-196 and BRII-198 monoclonal antibodies, alone or in combination, were safe and well-tolerated up to the highest doses tested of 3,000 mg for single mAbs and 1500/1500 mg for the combination...
Dec 23
2021
Self et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9 Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
15% higher mortality (p=0.72) and 7% improved recovery (p=0.48). RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit